Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis-Reference-Cited by-同舟云学术

Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis

Published:2022-11 Issue: Volume:136 Page:155291
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Marku Algerta,Da Dalt Lorenzo,Galli Alessandra,Dule Nevia,Corsetto Paola,Rizzo Angela Maria,Moregola Annalisa,Uboldi Patrizia,Bonacina Fabrizia,Marciani Paola,Castagna Michela,Catapano Alberico Luigi,Norata Giuseppe Danilo,Perego Carla

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference60 articles.

1. Reduced glucose-induced first-phase insulin release is a danger signal that predicts diabetes;Weir;J Clin Investig,2021

2. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects*;Perley;J Clin Invest,1967

3. Diabetic dyslipidaemia: from basic research to clinical practice*;Taskinen;Diabetologia,2003

4. Diabetic dyslipidemia;Chahil;Endocrinol Metab Clin North Am,2006

5. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction;Hao;Diabetes,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRG15 aggravates sepsis-related liver injury by promoting PCSK9 synthesis and secretion;International Immunopharmacology;2024-10

2. Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing;Science China Life Sciences;2024-08-15

3. Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations;Frontiers in Pharmacology;2024-07-30

4. Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis and treatment;American Journal of Physiology-Endocrinology and Metabolism;2024-07-01

5. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9;European Journal of Clinical Investigation;2024-06-26